Articles Posted in Product Liability

Yaz is a relatively new oral birth control medication. But an unfortunate number of patients have found, Yaz also causes serious, and life-threatening side effects including pulmonary embolism (blood clots to the lung), heart attack and stroke.

Bayer HealthCare Pharmaceuticals Inc. – the drug’s manufacturer – before being regulated by the U.S. Food and Drug Administration in a recent mandate, marketed Yaz which minimized these very serious side effects, and misleading millions of women about the safety of this medication.

If you’re taking the prescription medication Yaz or Yasmin, also manufactured by Bayer, and have had any of the side effects associated with these compounds, you may be entitled to compensation.

Continue reading

Recent reports have noted possible dangers of Yasmin/Yaz in persons with some preexisting conditions. Federal lawsuits filed recently allege that since Yasmin and Yaz have been available, there have been over 50 related deaths and hundreds of serious health concerns due to complications with the medicine.

Yasmin and Yaz lawsuits filed allege that Bayer failed to adequately warn about the increased risk of serious heart and health problems associated with their birth control when compared to other available pills. They not only minimized the blood clot risk with Yaz and Yasmin, but also heavily marketing the drugs through deceptive advertisements designed to encourage doctors and patients to use their birth control pill over other available forms that may not present as great of a risk.

Continue reading

A panel of federal judges will hear arguments later in September to determine whether all federal lawsuits against Bayer Pharmaceuticals Corporation over serious and potentially life threatening side effects of Yaz and Yasmin birth control should be centralized and consolidated in one district for coordinated handling as part of an MDL, or Multidistrict Litigation.

According to a notice recently issued by the U.S. Judicial Panel on Multidistrict Litigation, a hearing will be held on September 24 to consider whether the cases filed in various federal districts throughout the United States involve sufficiently common questions of fact and whether consolidation is appropriate.

Continue reading

Yasmin was first approved by The Food & Drug Administration (FDA) in 2001 for women to use as birth control.

In 2008, the FDA issued Bayer Corp. a warning letter regarding false claims made in two Yaz television commercials. These false claims involved the ability of Yaz to treat premenstrual syndrome (PMS) and all types of acne. As a result, the company stopped running the ads, and later embarked on an advertising campaign that corrected the deceptive claims made in those commercials.

Yasmin has been associated with:

– Pulmonary Embolism (PE)
– Deep Vein Thrombosis (DVT)
– Heart Attack
– Stroke
– Death

Continue reading

Yasmin and Yaz are two types of birth control oral contraceptive pills manufactured by Bayer Healthcare, and the generic, Ocella, is marketed and distributed by Barr Laboratories, Inc. Yasmin and Yaz contain the same estrogenic compound, ethinyl estradiol, that has been used in oral contraceptive “The Pill” since the 1970s, but the progestin in Yasmin and Yaz is new. Yasmin and Yaz both contain drospirenone, a “fourth generation” progestin – no other birth control oral contraceptive pills contain drospirenone, except for a recently approved generic version, Ocella.

If you have side effects from using these medications you can report them to the FDA.

Continue reading

Doctors should prescribe the birth- control pills that are the least likely to cause blood clots, according to a study of more than 3,000 women published today in the British Medical Journal.

Oral contraceptives containing levonorgestrel and a low dose of estrogen, such as Bayer AG’s Microgynon 30, were associated with the lowest risk of blood clots in the leg or lungs, researchers at Leiden University Medical Center in the Netherlands found. Birth-control pills containing desogestrel, cyproterone acetate or drospirenone carried about 1.5 to 2 times the risk of clots, they found.

Continue reading